Citrate targets FBPase and constitutes an emerging novel approach for cancer therapy

Gao-Min Liu and Yao-Ming Zhang recently published a review entitled «Targeting FBPase is an emerging novel approach for cancer therapy» (Liu and Zhang in Cancer Cell Int 18:36, 2018). In this paper, the authors highlighted how the down regulation or inactivation of FBPase, a rate limiting enzyme of...

Full description

Saved in:
Bibliographic Details
Published in:Cancer cell international 2018-11, Vol.18 (1), p.175-175, Article 175
Main Authors: Icard, Philippe, Fournel, Ludovic, Coquerel, Antoine, Gligorov, Joseph, Alifano, Marco, Lincet, Hubert
Format: Article
Language:English
Subjects:
Apoptosis
Cancer
Cancer metabolism
Cancer therapies
Cancer therapy
Cell cycle
Cell growth
Citrate
Citric acid
Cyclin-dependent kinases
Enzymes
Fatty acids
FBPase
Gluconeogenesis
Inactivation
Kinases
Medical prognosis
Metabolism
Thoracic surgery
Warburg effect
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gao-Min Liu and Yao-Ming Zhang recently published a review entitled «Targeting FBPase is an emerging novel approach for cancer therapy» (Liu and Zhang in Cancer Cell Int 18:36, 2018). In this paper, the authors highlighted how the down regulation or inactivation of FBPase, a rate limiting enzyme of gluconeogenesis, can promote the Warburg effect and cancer growth. In contrast, activation of this enzyme demonstrates anti-cancer effects and may appear as emerging novel approach for cancer therapy. Among the potential activators of FBP listed by Liu and Zhang, citrate was surprisingly not mentioned although it is an activator of FBPase, also demonstrating various anti-cancer effects in pre-clinical studies. Thus, citrate should be tested as a new therapeutic strategy, in particular in clinical studies.
ISSN:1475-2867
1475-2867
DOI:10.1186/s12935-018-0676-y